Ed Silverman at STAT reports that Congress has linked increased research funding to “fast-track” approval procedures. “By linking the extra funds to speedier approvals, Congress appears ready to undermine regulatory standards. And this is a misguided notion that, unfortunately, is more likely to help companies than patients.”
